Thursday, May 16th, 2024
To bring the patient perspective to the forefront of the drug development process, the GBS|CIDP Foundation is proud to announce that we are hosting an externally led Patient Focused Drug Development (EL PFDD) meeting on May 16th to elevate the patient voice of those with MMN, GBS, and Anti-Mag. With an audience consisting of regulators and researchers who are involved in the drug development process, this meeting will highlight the needs and preferences of the MMN, GBS, and Anti-Mag patient communities.
Join us on Thursday, May 16th, 2024 for the Virtual EL PFDD All-Day Meeting. All times listed reflect Eastern Time (ET).
What is Patient-Focused Drug Development?
Patient-Focused Drug Development (PFDD) is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.
FDA’s Role in Medical Product Development and Evaluation
One of FDA’s missions is to protect and promote public health by evaluating the safety and effectiveness of new drugs, biologics, and devices. FDA does not develop drugs nor conduct clinical trials. FDA does, however, play a constructive role in guiding, helping, or evaluating at some stages of the pre-clinical, translational, and clinical development work.
Learn more about EL PFDD Meetings
Meet the Panelists
GBS Panelists
MMN Panelists
Anti-Mag Panelists
Thank You to Our Sponsors!
